The initials CEO, CFO and COO have become so ubiquitous that it's no longer necessary to spell out what they stand for. (I hope.)

Pfizer's recent decision to pull the plug on direct funding of CME through independent commercial providers follows months of public criticism of pharma support. Lew Miller and Warren Ross explore how the rest of the industry is coping with the assault

One of the most useful skills I learned in high school was how to write book reports without reading the whole book.

The pioneers of biotech began their journey with an endless level of optimism and promise. So, why has the goal of redefining the landscape and achieving the blockbuster success the likes of Big Pharma proven so elusive?

It's become part of received wisdom that today's patient is an active partner in his or her medical care. Since we all accept this as fact, we don't think it's worth questioning.

Success! When Congress was debating the new Medicare drug benefit, the pharmaceutical industry's top priority was to make sure the government could not negotiate prescription drug prices.

What, if anything, is wrong with FDA? And who's to blame: the agency's leadership or its massed ranks of critics? These are just some of the questions Warren Ross posed to an opinionated panel of agency alumni and observers in the know

Pardon my French, but there's no better cliché to describe a special issue of Harper's magazine dated October 1960, starting with the cover headline: "The Crisis in American Medicine."

Few analysts have proved as prescient over the years as Morgan Stanley's Jami Rubin, recently ranked third among industry analysts by Institutional Investor.

When the members of the FDA advisory committee voted 22 to 1 to keep Avandia on the market, they had concluded that the epidemiologic data showed that the benefits of the drug outweighed the risks.